MK-0429   Click here for help

GtoPdb Ligand ID: 9689

Synonyms: compound 6 [PMID:14561098] [1] | MK-429 | MK0429
Compound class: Synthetic organic
Comment: MK-0429 is an orally active, non-peptide inhibitor/antagonist of αv integrins [1-2,4]. It was initially identified as a clinical lead with potential utility for the prevention and treatment of osteoporosis [1], but has since shown activity in other biological settings. MK-0429 binds to the αv's Arg-Gly-Asp (RGD)-motif binding domain (the RGD-motif is a conserved sequence in proteins that bind to αv integrins), thereby preventing interaction with RGD-containing binding partners such as osteopontin, bone sialoprotein, vitronectin, and fibrinogen.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 107.89
Molecular weight 439.22
XLogP 1.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cn1)C(N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O
Isomeric SMILES COc1ccc(cn1)[C@@H](N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O
InChI InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1
InChI Key HGFOOLONGOBCMP-IBGZPJMESA-N
No information available.
Summary of Clinical Use Click here for help
MK-0429 has completed a Phase 2 proof-of-concept clinical trial in post-menopausal women that was designed to evaluate the compound's effect on bone resorption and mineral density (NCT00533650), and a Phase 1 study in prostate cancer patients with bone metastases (NCT00302471) [3].